Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids

Journal of Lipid Research

Volumn 45, Issue 12, 2004, Pages 2211-2220

  Nguyen, Su Duy ^a   Sok, Dai Eun ^a  

^a Chungnam National University   (South Korea)

Author keywords

Lysophospholipids; Oxidative inactivation; Paraoxonase 1; Phospholipid

Indexed keywords

ALDEHYDE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLGLYCEROL; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHATIDYLSERINE; OLEIC ACID; OLEOYLGLYCINE; OXIDIZING AGENT; PALMITOLEIC ACID; PARAOXON; PHENYLACETIC ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; LIPID METABOLISM; LIPID OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ARYLDIALKYLPHOSPHATASE; HUMANS; KINETICS; LIPID METABOLISM; REACTIVE OXYGEN SPECIES;

EID: 10044283247     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M400144-JLR200     Document Type: Article

References (60)

1. La Du, B. N. 1996. Structural and functional diversity of paraoxonase. Nat. Med. 2: 1186-1187.
2. Berliner, J. A., M. Navab, A. M. Fogelman, J. S. Frank, L. L. Demer, P. A. Edwards, A. D. Watson, and A. J. Lusis. 1995. Atherosclerosis: basic mechanism, oxidation, inflammation and genetics. Circulation. 91: 2488-2496.
3. Mackness, M. I., B. Mackness, P. N. Durrington, P. W. Connelly, and R. A. Hegele. 1996. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7: 69-76.
4. Davies, H. G., R. J. Richter, M. Keifer, C. A. Broomfield, J. Sowalla, and C. E. Furlong. 1996. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14: 334-336.
5. Gan, K. N., A. Smolen, H. W. Eckerson, and B. N. La Du. 1991. Purification of human serum paraoxonase/arylesterase. Drug Metab. Dispos. 19: 100-106.
6. Jakubowski, H. 2000. Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275: 3957-3962.
7. Shih, D. M., L. Gu, Y-R. Xia, M. Navab, W-F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, and A. J. Lusis. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
8. Billecke, S., D. Draganov, R. Counsell, P. Stetson, C. Watson, C. Hsu, and B. N. La Du. 2000. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28: 1335-1342.
9. Ferguson, E., S. Parthasarathy, J. Joseph, and B. Kalyanaraman. 1998. Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low density lipoprotein. J. Lipid Res. 39: 925-933.
10. Teiber, J. F., D. I. Draganov, and B. N. La Du. 2003. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol. 66: 887-896.
11. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Fauli, A. M. Fogelman, and N. Mohamad. 1995. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
12. Aviram, M., M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C. L. Bisgaier, R. S. Newton, and B. La Du. 1999. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radice. Biol. Med. 26: 892-904.
13. Shih, D. M., L. Gu, S. Hama, Y-R. Xia, M. Navab, A. M. Fogelman, and A. J. Lusis. 1996. Genetic dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97: 1630-1639.
14. Aviram, M., E. Hardak, J. Vaya, S. Mahmood, S. Milo, A. Hoffman, S. Billicke, D. Draganov, and M. Rosenblat. 2000. Human serum paraoxonase (PON 1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 101: 2510-2517.
15. Ruiz, J., H. Blanche, R. W. James, M. C. Garin, C. Vaisse, G. Charpentier, N. Cohen, A. Morabia, P. Passa, and P. Froguel. 1995. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 30: 869-872.
16. Mackness, B., G. K. Davies, W. Turkic, E. Lee, D. H. Roberts, E. Hill, C. Roberts, P. N. Durrington, and M. I. Mackness. 2001. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21: 1451-1457.
17. Mackness, B., P. N. Durrington, and M. I. Mackness. 2002. The paraoxonase gene family and coronary heart disease. Curr. Opin. Lipidol. 13: 357-362.
18. Bargota, R. S., M. Akhtar, K. Biggadike, D. Gani, and R. K. Allemann. 2003. Structure-activity relationship on human serum paraoxonase (PON1) using substrate analogues and inhibitors. Bioorg. Med. Chem. Lett. 13: 1623-1626.
19. Echjkerson, H. W., C. M. Wyle, and B. N. La Du. 1983. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35: 1126-1138.
20. Aviram, M., M. R. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
21. Adkins, S., K. N. Can, M. Mody, and B. N. La Du. 1993. Molecular basis for the polymorphic forms of human serum paraoxonase/ arylesterase: glutamine or arginine at position 191 for the respective A or B allozymes. Am. J. Hum. Genet. 52: 598-608.
22. Jarvik, G. P., T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, P. J. Heagerty, and C. E. Furlong. 2003. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 1465-1471.
23. Mackness, B., P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness. 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 107: 2775-2779.
24. Senti, M., M. Tomas, M. Filo, T Weinbrenner, M. I. Covas, J. Sala, R. Masia, and J. Marrugal. 2003. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88: 5422-5426.
25. Paragh, G., P. Balla, E. Katona, I. Seres, A. Egerhazi, and I. Degrell. 2002. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci. 252: 63-67.
26. James, R. W., I. Leviev, and A. Righelti. 2000. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation. 101: 2252-2257.
27. Seres, I., G. Paragh, E. Deschene, Jr., T. Fulop, and A. Khalil. 2003. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp. Gerontol. 39: 59-66.
28. Aviram, M., S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblat, J. Hsu, C. Erogul, C. Dunlop, and B. N. La Du. 1998. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Arterioscler. Thromb. Vasc. Biol. 18: 1617-1624.
29. Berliner, J. A., and J. W. Heinecke. 1996. The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20: 707-727.
30. Burkitt, M. J. A. 2001. Critical overview of the chemistry of copper-dependent low density lipoprotein oxidation: roles of lipid hydroperoxides, alpha-tocopherol, thiols, and ceruloplasmin. Arch. Biochem. Biophys. 394: 117-135.
31. Jaouad, L., C. Milochevitch, and A. Khalil. 2003. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic. Res. 37: 77-83.
32. Nguyen, S. D., and D-E. Sok. 2003. Oxidative inactivation of paraoxnasel, an antioxidant protein and its effect on antioxidant action. Free Radic. Res. 37: 1319-1330.
33. La Du, B. N., S. Adkins, C. L. Kuo, and D. Lipsig. 1993. Studies on human serum paraoxonase/arylesterase. Chem. Biol. Interact. 87: 25-34.
34. Nguyen, S. D., and D-E. Sok. 2003. Beneficial effect of oleoylated lipids on paraoxonase1: protection against oxidalive inactivation and stabilization. Biochem. J. 375: 275-285.
35. Francone, O. L., P. V. Subbaiah, A. van Tol, L. Royer, and M. Haghpassand. 2003. Abnormal phospholipid composition impairs HDL biogenesis and maturation in mice lacking Abcal. Biochemistry. 42: 8569-8578.
36. Fobker, M., R. Voss, H. Reinecke, C. Crone, G. Assmann, and M. Walter. 2001. Accumulation of cardiolipin and lysocarcliolipin in fibroblasts from Tangier disease subjects. FEBS Lett. 500: 157-162.
37. Tigyi, G., and A. L. Parrill. 2003. Molecular mechanisms of lysophosphatidic acid action. Prog. Lipid Res. 42: 498-526.
38. Paradies, G., G. Petrosillo, M. Pistolese, N. Di Venosa, A. Federici, and F. Maria Ruggiero. 2004. Decrease in mitochondria! complex I activity in ischemic/reperfused ral heart. Involvement of reactive oxygen species and cardiolipin. Circ. Res. 94: 53-59.
39. Kuo, C-L., and B. N. La Du. 1995. Comparison of purilied human and rabbit serum paraoxonases. Drug Metah. Dispos. 23: 935-944.
40. Lo, T. W., M. E. Westwood, A. C. McLellan, T. Sehvood, and P. J. Thornalley. 1994. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J. Biol. Chem. 269: 32299-32305.
41. Michaela, S-F., P. L. Maden, D. Manner, A. M. Blamire, R. E. Buckingham, P. Styles, K. R. George, S. Neubauer, and K. Clarke. 2003. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 107: 3040-3046.
42. Esterbauer, H., R. Schaur, and H. Zollner. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free. Radic. Biol. Med. 11: 81-128.
43. Sorenson, R. C., S. L. Primo-Parmo, O. L. Kuo, S. Adkins, O. Lockridge, and B. N. La Du. 1995. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. USA. 92: 7186-7191.
44. Tomas, M., M. Senti, F. Garcia-Faria, J. Vila, A. Torrents, M. Covas, and J. Marrugat. 2000. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20: 2113-2119.
45. Senti, M., M. Tomas, M. Fito, T. Weinbrenner, M. I. Coras, J. Sala, R. Masia, and J. Marrugal. 2003. Anlioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88: 5422-5426.
46. Ikeda, Y., T. Suehiro, M. Inone, Y. Nakauchi, T. Morita, K. Arii, H. Ito, Y. Kumon, and K. Hashimoto. 1998. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes niellilus. Metabolism. 47: 598-602.
47. Humbert, R., D. A. Adler, C. M. Disteche, C. Hassett, C. J. Omiecinski, and C. E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Ganet. 3: 73-76.
48. Nguyen, S. D., and D-E. Sok. 2003. Protection by fatty acids against cuniene hydroperoxide-induced inactivation of paraoxonase1. J. Pharm. Sci. 18: 32-36.
49. Doorn, J. A., R. C. Sorenson, S. S. Billecke, C. Hsu, and B. N. La Du. 1999. Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase. Chem. Biol. Interact. 119-120: 235-241.
50. Uchida, K., and E. R. Stadtman. 1992. Selective cleavage of thioester linkage in proteins modified with 4-hydroxynonenal. Proc. Natl. Acad. Sci. USA. 89: 5611-5615.
51. Gonzalvo, M. C., F. Gil, A. F. Hernandez, E. Villanueva, and A. Pla. 1997. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem. Biol. Interact. 105: 169-179.
52. Nguyen, S. D., and D-E. Sok. 2003. Protective action of CLA against oxidative inactivation of paraoxonase1, an antioxidant enzyme. Lipids. 38: 615-622.
53. Vega, G. L., N. B. Cater, D. R. Hadizadeh, and S. M. Grundy. 2003. Free fairy acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin. Pharmacol. Ther. 74: 236-244.
54. Lewis, G. F., A. Carpentier, K. Adeli, and A. Giacca. 2002. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 23: 201-229.
55. Garavito, R. M., and S. Ferguson-Miller. 2001. Detergents as tools in membrane biochemistry. J. Biol. Chem. 276: 32403-32406.
56. 2+ and phospholipids. J. Biol. Chem. 261: 15424-15429.
57. Stafford, R. E., T. Fanni, and E. A. Dennis. 1989. Interfacial properties and critical micelle concentration of lysophospholipids. Biochemistry. 28: 5113-5120.
58. Ishimoto, Y., K. Yamada, S. Yamamoto, T. Ono, M. Notoya, and K. Hanasaki. 2003. Group V and X secretory pliospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim. Biophys. Acta. 1642: 129-138.
59. Benitez, S., J. L. Sanchez-Quesada, V. Ribas, O. Jorba, F. Blanco-Vaca, F. Gonzalez-Sastre, and J. Ordonez-Llanos. 2003. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation. 8: 92-96.
60. Yokoyama, K., F. Shimizu, and M. Setaka. 2000. Simultaneous separation of lysophospholipids from the total lipid fraction of crude biological samples using two-dimensional thin layer chromatography. J. Lipid Res. 41: 142-147.